Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Pharmalittle: We’re reading about Sanders and Novo Nordisk CEO sparring, Roche refocusing, and more

Hello, everyone, and how are you today? We are doing just fine, thank you, and given that the middle of the week is here, we

September 25, 2024

AI Research: AI-Powered Brain Scans May Aid in ADHD Diagnosis

What You Should Know: – Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers found

December 2, 2023

Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

March 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.